tradmap

FDMT Earnings 4d Molecular Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$3 -$2 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $43M $85M 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$161M -$80M $0 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$3 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
-$19000 $43M $85M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$73M -$27M $19M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–21 of 21
Q2 20262026-06-30-2.052026-08-1310-Q
Q1 20262026-03-31-1.012026-05-0710-Q
FY 20252025-12-31-2.422026-03-1810-K
Q3 20252025-09-30-2.852025-11-1010-Q
Q2 20262025-06-30-1.842026-08-1310-Q
Q1 20262025-03-31-0.862026-05-0710-Q
FY 20252024-12-31-2.982026-03-1810-K
Q3 20252024-09-30-2.082025-11-1010-Q
Q2 20252024-06-30-1.292025-08-1110-Q
Q1 20252024-03-31-0.662025-05-0810-Q
FY 20242023-12-31-2.582025-02-2810-K
Q3 20242023-09-30-1.812024-11-1310-Q
Q2 20242023-06-30-1.632024-08-0810-Q
Q1 20242023-03-31-0.882024-05-0910-Q
FY 20232022-12-31-3.322024-02-2910-K
Q3 20232022-09-30-2.482023-11-0910-Q
Q2 20232022-06-30-1.692023-08-0910-Q
Q1 20232022-03-31-0.822023-05-1110-Q
FY 20222021-12-31-2.572023-03-1510-K
Q3 20222021-09-30-1.722022-11-0810-Q
Q2 20222021-06-30-0.902022-08-1110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.